Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$9.18 USD
+0.08 (0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.19 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
PHAT 9.18 +0.08(0.88%)
Will PHAT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHAT
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
3 Top Breakout Stocks Worth a Buy for Attractive Returns
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
Other News for PHAT
Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals’ V oquezna
Commit To Buy Phathom Pharmaceuticals At $7.50, Earn 28.2% Annualized Using Options
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oquezna
Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)